Camurus Navigation ABOUT CAMURUS CEO statement Management team Board of directors Career Code of conduct PIPELINE CAM2038 Opioid Dependence CAM2029 Growth Hormone Disorders CAM2038 Chronic Pain CAM2032 Prostate Cancer episil® Oral Liquid TECHNOLOGIES FluidCrystal® injection depot FluidCrystal® topical bioadhesive FluidCrystal® nanoparticles INVESTORS Press releases Events & Presentations Financial calendar Financial reports Share & Shareholders Annual general meeting Corporate governance Subscription Risk Factors MEDIA CONTACT ABOUT CAMURUS CEO statement Management team Board of directors Career Code of conduct PIPELINE CAM2038 Opioid Dependence CAM2029 Growth Hormone Disorders CAM2038 Chronic Pain CAM2032 Prostate Cancer episil® Oral Liquid TECHNOLOGIES FluidCrystal® injection depot FluidCrystal® topical bioadhesive FluidCrystal® nanoparticles INVESTORS Press releases Events & Presentations Financial calendar Financial reports Share & Shareholders Annual general meeting Corporate governance Subscription Risk Factors MEDIA CONTACT THE CAMURUS SHARE 93.60 SEK -1.16% XSTO 2018-08-31 17:29 THE CAMURUS SHARE 93.60 SEK -1.16% XSTO 2018-08-31 17:29 ABOUT CAMURUS Delivering better treatments Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. More about Camurus ABOUT CAMURUS Delivering better treatments Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. More about Camurus 31 AUGUST – INTERNATIONAL OVERDOSE AWARENESS DAY PRESS RELEASES 2018-07-17 Interim Report... 2018-07-16 Camurus announces PDUFA... 2018-06-29 Change in the number of... 2018-06-29 Camurus has completed a... Archive FINANCIAL CALENDAR 2018-10-25 Interim Report January-September... See more EVENTS & PRESENTATIONS 2018-09-06 Pareto Securities... 2018-09-10 Nordic Life Science Days 2018-10-09 CPhI Worldwide 2018-10-17 Partnership Opportunities... See more DEVELOPMENT PIPELINE Transforming treatments for patients with serious and chronic diseases Camurus’ clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. See our pipeline DEVELOPMENT PIPELINE Transforming treatments for patients with serious and chronic diseases Camurus’ clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. See our products CAM2038 OPIOID DEPENDENCE CAM2029 GROWTH HORMONE DISORDERS CAM2038 CHRONIC PAIN CAM2032 PROSTATE CANCER EPISIL® ORAL LIQUID INVESTOR RELATIONS Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us. Investor relations INVESTOR RELATIONS Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us. Investor relations Enthusiasm for upcoming clinical, regulatory and commercial milestones Fredrik Tiberg CEO Statement CAM2038 has the potential to become a game-changer in opioid dependence treatment Fredrik Tiberg CEO Statement TECHNOLOGIES FluidCrystal®– smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. Technologies TECHNOLOGIES FluidCrystal® – smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. Technologies FluidCrystal® INJECTION DEPOT FluidCrystal® TOPICAL BIOADHESIVE FluidCrystal® NANOPARTICLES Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Sölvegatan 41 A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com About Camurus Pipeline Technologies Investors Career Legal notice Privacy policy Contact IR contact By continuing to use the site, you agree to the use of cookies. more information Accept The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Close